BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, Mekky MA, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutumi H, Fujiyoshi T, Sato T, Hieda N, Yoshida T, Okuno N, Shimizu Y, Yatabe Y, Niwa Y, Yamao K. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol. 2015;50:564-572. [PMID: 25142799 DOI: 10.1007/s00535-014-0987-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Tanaka H, Hijioka S, Hosoda W, Ueno M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Komoto I, Tsuji A, Hashigo S, Kanno A, Miyabe K, Takagi T, Ishii H, Kojima Y, Yoshitomi H, Yanagimoto H, Furuse J, Mizuno N. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. Pancreatology 2020;20:1421-7. [PMID: 32891532 DOI: 10.1016/j.pan.2020.07.400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol 2017; 23(3): 516-524 [PMID: 28210088 DOI: 10.3748/wjg.v23.i3.516] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
3 Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, Fazio N, Delle Fave G. Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Pancreas 2017;46:302-5. [DOI: 10.1097/mpa.0000000000000762] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 5.4] [Reference Citation Analysis]
4 Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 2020;16:590-607. [PMID: 32839579 DOI: 10.1038/s41574-020-0391-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
5 Scoazec JY, Couvelard A; Réseau TENpath. [Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future]. Ann Pathol 2017;37:444-56. [PMID: 29169836 DOI: 10.1016/j.annpat.2017.10.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
6 Jubashi A, Yamaguchi D, Ogata R, Nagatsuma G, Hara Y, Tanaka Y, Yoshioka W, Hino N, Morisaki T, Ario K, Matsuoka Y, Taba M, Naito S, Tsunada S. A case of pancreatic endocrine carcinoma with a different clinical diagnosis before chemotherapy and pathological autopsy. Clin J Gastroenterol 2021. [PMID: 34689312 DOI: 10.1007/s12328-021-01538-9] [Reference Citation Analysis]
7 Kogami T, Iwai T, Kida M, Okuwaki K, Hasegawa R, Kurosu T, Watanabe M, Matsushita M, Imawari K, Adachi K, Tadehara M, Tamaki A, Imaizumi H, Koizumi W. A case of pancreatic neuroendocrine carcinoma with a favorable clinical response to pembrolizumab. Clin J Gastroenterol 2021;14:1804-10. [PMID: 34495482 DOI: 10.1007/s12328-021-01505-4] [Reference Citation Analysis]
8 Kang JS, Lee KB, Choi YJ, Byun Y, Han Y, Kim H, Kwon W, Jang JY. A comparison of outcomes in patients with intracholecystic papillary neoplasms or conventional adenocarcinomas of the gallbladder. HPB (Oxford) 2021;23:746-52. [PMID: 33092965 DOI: 10.1016/j.hpb.2020.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 De Caro MLDB, Guadagno E, De Rosa G. Pathological Classification: GEP, TNET, and Rare Forms. In: Colao A, Faggiano A, de Herder W, editors. Neuroendocrine Tumors in Real Life. Cham: Springer International Publishing; 2018. pp. 29-49. [DOI: 10.1007/978-3-319-59024-0_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Saeger W, Schnabel PA, Komminoth P. Grading neuroendokriner Tumoren. Pathologe 2016;37:304-13. [DOI: 10.1007/s00292-016-0186-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology 2020;145:102835. [DOI: 10.1016/j.critrevonc.2019.102835] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
12 Guilmette JM, Nosé V. Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. Adv Anat Pathol 2019;26:13-30. [PMID: 29912000 DOI: 10.1097/PAP.0000000000000201] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 10.7] [Reference Citation Analysis]
13 Zatelli MC, Guadagno E, Messina E, Lo Calzo F, Faggiano A, Colao A, _ _. Open issues on G3 neuroendocrine neoplasms: back to the future. Endocrine-Related Cancer 2018;25:R375-84. [DOI: 10.1530/erc-17-0507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Zamir MA, Hakim W, Yusuf S, Thomas R. Imaging of Pancreatic-Neuroendocrine Tumours: An Outline of Conventional Radiological Techniques. CRP 2019;12:135-55. [DOI: 10.2174/1874471012666190214165845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Mafficini A, Scarpa A. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev 2019;40:506-36. [PMID: 30657883 DOI: 10.1210/er.2018-00160] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 20.0] [Reference Citation Analysis]
16 Miki M, Kawabe K, Igarashi H, Abe T, Ohishi Y, Hashimoto R, Karashima T, Yamasaki I, Inoue K, Ito T, Ogawa Y. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease. Intern Med 2018;57:2007-11. [PMID: 29491307 DOI: 10.2169/internalmedicine.0416-17] [Reference Citation Analysis]
17 Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N. Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. Ann Surg Oncol 2019;26:1385-93. [PMID: 30863939 DOI: 10.1245/s10434-019-07252-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
18 Bergsland EK, Woltering EA, Rindi G, O’dorisio TM, Schilsky RL, Liu EH, Kim MK, Nakakura EK, Reidy-lagunes DL, Strosberg JR, Tang LH, Vinik AI, Wang Y, Asare EA, Brierley JD, Bushnell DL, Jensen RT, Pommier RF, Wolin EM, Wong RK, Klimstra DS. Neuroendocrine Tumors of the Pancreas. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. Cham: Springer International Publishing; 2017. pp. 407-19. [DOI: 10.1007/978-3-319-40618-3_34] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Pea A, Hruban RH, Wood LD. Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Rev Gastroenterol Hepatol. 2015;9:1407-1419. [PMID: 26413978 DOI: 10.1586/17474124.2015.1092383] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
20 Karakaş Y, Laçin Ş, Kurtulan O, Esin E, Sunar V, Sökmensüer C, Kılıçkap S, Yalçin Ş. Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience. Turk J Gastroenterol 2020;31:91-8. [PMID: 32141816 DOI: 10.5152/tjg.2020.18919] [Reference Citation Analysis]
21 Hamano Y, Moriwaki T, To K, Watahiki T, Yamada T, Sakashita S, Hyodo I. A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression. Intern Med 2019;58:1087-91. [PMID: 30568142 DOI: 10.2169/internalmedicine.1809-18] [Reference Citation Analysis]
22 Bergsland EK, Woltering EA, Rindi G, O’dorisio TM, Schilsky RL, Liu EH, Kim MK, Nakakura EK, Reidy-lagunes DL, Strosberg JR, Tang LH, Vinik AI, Wang Y, Asare EA, Brierley JD, Bushnell DL, Jensen RT, Pommier RF, Wolin EM, Wong RKS, Klimstra DS. Neuroendocrine Tumors of the Duodenum and Ampulla of Vater. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC Cancer Staging Manual. Cham: Springer International Publishing; 2017. pp. 361-73. [DOI: 10.1007/978-3-319-40618-3_30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
24 Lee L, Ito T, Igarashi H, Ueda K, Fujiyama T, Kawabe K, Ogawa Y. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. J Hepatobiliary Pancreat Sci 2017;24:95-102. [DOI: 10.1002/jhbp.418] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
25 von Arx C, Capozzi M, López-Jiménez E, Ottaiano A, Tatangelo F, Di Mauro A, Nasti G, Tornesello ML, Tafuto S. Updates on the Role of Molecular Alterations and NOTCH Signalling in the Development of Neuroendocrine Neoplasms. J Clin Med 2019;8:E1277. [PMID: 31443481 DOI: 10.3390/jcm8091277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
26 Kang XN, Zhang XY, Bai J, Wang ZY, Yin WJ, Li L. Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm. World J Gastrointest Oncol 2019; 11(5): 436-448 [PMID: 31139313 DOI: 10.4251/wjgo.v11.i5.436] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
28 Girardi DM, Silva ACB, Rêgo JFM, Coudry RA, Riechelmann RP. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev 2017;56:28-35. [PMID: 28456055 DOI: 10.1016/j.ctrv.2017.04.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
29 Teo RYA, Teo TZ, Tai DWM, Tan DM, Ong S, Goh BKP. Systematic review of current prognostication systems for pancreatic neuroendocrine neoplasms. Surgery 2019;165:672-85. [PMID: 30558808 DOI: 10.1016/j.surg.2018.10.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
30 Ito T, Hijioka S, Masui T, Kasajima A, Nakamoto Y, Kobayashi N, Komoto I, Hijioka M, Lee L, Igarashi H, Jensen RT, Imamura M. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol 2017;52:9-18. [PMID: 27539256 DOI: 10.1007/s00535-016-1250-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
31 Fabbri A, Cossa M, Sonzogni A, Papotti M, Righi L, Gatti G, Maisonneuve P, Valeri B, Pastorino U, Pelosi G. Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. Virchows Arch 2017;470:153-64. [PMID: 28054150 DOI: 10.1007/s00428-016-2062-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
32 Zhang MY, He D, Zhang S. Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. World J Gastrointest Oncol 2020; 12(7): 705-718 [PMID: 32864039 DOI: 10.4251/wjgo.v12.i7.705] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Mizuno Y, Kudo A, Akashi T, Akahoshi K, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tateishi U, Tanabe M. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 2018;144:1155-63. [PMID: 29602973 DOI: 10.1007/s00432-018-2636-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
34 Tanaka H, Matsusaki S, Baba Y, Isono Y, Kumazawa H, Sase T, Okano H, Saito T, Mukai K, Kaneko H. Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate. Clin J Gastroenterol. 2015;8:414-420. [PMID: 26439620 DOI: 10.1007/s12328-015-0609-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
35 Gao G, Qorbani A, Zhou CH. A pancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) (NET and undifferentiated carcinoma of the pancreas with osteoclast-like giant cells) with metastatic neuroendocrine component to the liver. Autops Case Rep 2021;11:e2020201. [PMID: 34277482 DOI: 10.4322/acr.2020.201] [Reference Citation Analysis]
36 Amair-Pinedo F, Matos I, Saurí T, Hernando J, Capdevila J. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol 2017;12:757-74. [PMID: 29143176 DOI: 10.1007/s11523-017-0532-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Ohmoto A, Rokutan H, Yachida S. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. Int J Mol Sci 2017;18:E143. [PMID: 28098761 DOI: 10.3390/ijms18010143] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
38 Kimura T, Miyamoto H, Fukuya A, Kitamura S, Okamoto K, Kimura M, Muguruma N, Ikemoto T, Shimada M, Yoneda A, Bando Y, Takishita M, Takayama T. Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma. Clin J Gastroenterol. 2016;9:261-265. [PMID: 27262570 DOI: 10.1007/s12328-016-0655-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
39 Inzani F, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin North Am. 2018;47:463-470. [PMID: 30098710 DOI: 10.1016/j.ecl.2018.04.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 17.8] [Reference Citation Analysis]
40 Yanagihara K, Kubo T, Mihara K, Kuwata T, Ochiai A, Seyama T, Yokozaki H. Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma. Oncotarget 2018;9:36503-14. [PMID: 30559933 DOI: 10.18632/oncotarget.26367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
41 Wang M, Ding D, Qin T, Wang H, Liu Y, Liu J, Liu J, Zhang H, Zhao J, Wu CH, Javed A, Wolfgang C, Guo S, Chen Q, Zhao W, Shi W, Zhu F, Guo X, Li X, He R, Xu S, Edil B, Tien YW, Jin G, Zheng L, He J, Qin R; Minimally Invasive Pancreas Treatment Group in the Pancreatic Disease Branch of China's International Exchange and Promotion Association for Medicine and Healthcare. New staging classification for pancreatic neuroendocrine neoplasms combining TNM stage and WHO grade classification []. Cancer Lett 2021;518:207-13. [PMID: 34271105 DOI: 10.1016/j.canlet.2021.07.018] [Reference Citation Analysis]